Honigman Advises NeuroOne Medical Technologies Corporation on $8 Million Public Offering

NeuroOne Medical Technologies Corporation, a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, closed on April 7, 2025 its underwritten public offering of shares of common stock. Gross proceeds from the offering were $8 million, before deducting discounts and commissions and offering expenses. In addition, the company granted the underwriters a 45-day option to purchase up to an additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Honigman advised NeuroOne Medical Technologies Corporation in the offering and was led by corporate partners Phillip D. Torrence, Emily J. Johns and N. Danny Shulman, with associates Lauren Legner and Cassie J. O'Hagan.